An Open-label Trial of the Glutamate-modulating Agent Riluzole in Combination with Lithium for the Treatment of Bipolar Depression

Overview

Journal Biol Psychiatry

Publisher Elsevier

Specialty Psychiatry

Date 2005 Feb 12

PMID 15705360

Citations 98

Authors

Carlos A Zarate Jr

Jorge A Quiroz

Jaskaran B Singh

Kirk D Denicoff

Georgette De Jesus

David A Luckenbaugh

Dennis S Charney

Husseini K Manji

Affiliations

Soon will be listed here.

Abstract

Background: Preclinical and clinical evidence indicate that the glutamatergic system might play a role in the pathophysiology of mood disorders. This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression.

Methods: This was an 8-week add-on study of riluzole in combination with lithium in acutely depressed bipolar patients aged 18 years and older. After open treatment with lithium for a minimum period of 4 weeks, subjects who continued to have a Montgomery-Asberg Depression Rating Scale (MADRS) score of >/=20 received riluzole (50-200 mg/day) for 8 weeks.

Results: Fourteen bipolar depressed patients entered the study. The linear mixed models for total MADRS score showed a significant treatment effect. No switch into hypomania or mania was observed. Overall, riluzole was well tolerated.

Conclusions: Although preliminary, these results suggest that riluzole might indeed have antidepressant efficacy in subjects with bipolar depression.

Citing Articles

Correlations between multimodal neuroimaging and peripheral inflammation in different subtypes and mood states of bipolar disorder: a systematic review.

Long J, Li B, Ding P, Mei H, Li Y Int J Bipolar Disord. 2024; 12(1):5.

PMID: 38388844 PMC: 10884387. DOI: 10.1186/s40345-024-00327-w.

Electrochemical detection of the neurotransmitter glutamate and the effect of the psychotropic drug riluzole on its oxidation response.

Yu T, Cui J, Chen S Anal Bioanal Chem. 2024; 416(7):1707-1716.

PMID: 38363306 DOI: 10.1007/s00216-024-05175-2.

Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis.

Keifer Jr O, Gutierrez J, Butt M, Cramer S, Bartus R, Tansey M PLoS One. 2023; 18(8):e0277718.

PMID: 37607205 PMC: 10443869. DOI: 10.1371/journal.pone.0277718.

Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.

Bansal Y, Fee C, Misquitta K, Codeluppi S, Sibille E, Berman R Complex Psychiatry. 2023; 9(1-4):57-69.

PMID: 37101541 PMC: 10123365. DOI: 10.1159/000529534.

Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions.

Elsayed O, Ercis M, Pahwa M, Singh B Neuropsychiatr Dis Treat. 2022; 18:2927-2943.

PMID: 36561896 PMC: 9767030. DOI: 10.2147/NDT.S273503.